한글목차

세계 고인산혈증 치료제 시장 전망은 병원 및 클리닉 시장에서의 기회로 인해 유망한 것으로 평가되고 있습니다. 세계 고인산혈증 치료제 시장은 2025-2031년 연평균 4.9% 성장할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 만성 신장 질환의 유병률 증가, 효과적인 인산염 조절에 대한 수요 증가, 환자 결과 개선에 대한 관심 증가 등입니다.

• Lucintel의 예측에 따르면, 유형별로는 인산칼슘 바인더가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예측됩니다.
• 용도별로는 병원이 높은 성장이 예상됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장을 보일 것으로 예측됩니다.

고인산혈증 치료제 시장의 새로운 동향

새로운 트렌드는 보다 효과적이고 편리하며 표적화된 치료에 초점을 맞추면서 고인산혈증 치료제 시장을 재편하고 있습니다. 이러한 추세는 높은 약값 부담과 부작용 등 기존 치료법의 한계에 직접적으로 대응하는 것입니다. 이러한 추세는 치료의 개인화, 치료 순응도 향상, 환자의 장기적 결과 개선이 가능한 미래로 시장을 이끌고 있습니다.

• 비칼슘계 결합제로의 전환: 고칼슘혈증과 혈관 석회화에 대한 우려로 인해 칼슘계 인산염 결합제에서 탈피하는 것이 중요한 추세입니다. 그 영향은 더 안전한 치료 프로파일입니다. 새로운 비칼슘 바인더, 예를 들어 철이나 란탄 기반 바인더는 이러한 부작용의 위험 없이 효과적인 인산염 조절을 제공하여 CKD 환자의 심혈관계 결과를 개선할 수 있습니다.
• 신규 기전 개발: 시장에서는 NHE3 억제제와 같은 새로운 작용기전을 가진 약물의 개발이 활발히 이루어지고 있습니다. 그 영향은 약값 부담의 감소와 치료 옵션의 확대입니다. 장내 인산 흡수를 억제하는 테나파놀과 같은 약물은 고인산혈증에 대처하는 새로운 방법을 제공하며, 단독으로 또는 기존 결합제와 함께 사용할 수 있습니다.
• 알약 부담 감소에 초점: 큰 추세는 환자가 매일 복용하는 알약의 수를 줄이는 치료법 개발입니다. 그 결과, 환자의 복약 순응도가 개선되고 삶의 질이 향상됩니다. 기존 인산염 결합제의 높은 복약 부담은 복약 순응도를 저해하는 큰 장애물이므로, 복용 횟수가 적은 새로운 제형과 약물은 환자와 임상의로부터 높은 평가를 받고 있습니다.
• 기술과 디지털 건강의 통합: 시장에서는 치료 순응도를 높이기 위해 디지털 도구와 모바일 앱을 통합하는 경향이 증가하고 있습니다. 그 결과, 환자 참여와 관리가 향상됩니다. 이러한 도구는 환자의 인산 수치 추적, 식단 모니터링, 약물 복용 알림을 지원하여 약리학적 치료를 보완하고 전반적인 결과를 개선할 수 있습니다.
• 경구용 제제의 확대: 씹어먹는 정제, 현탁액 등 보다 기호성이 높고 편의성이 높은 경구용 제제의 개발이 주요 트렌드입니다. 그 결과, 환자의 편안함과 순응도가 크게 향상되었습니다. 이러한 제제는 정제를 삼키기 어려운 환자들에게 특히 유용하며, 보다 친숙하고 내약성이 높은 치료법을 제공합니다.

이러한 새로운 트렌드는 고인산혈증 치료제 시장을 환자 중심의 치료 모델로 전환함으로써 고인산혈증 치료제 시장을 근본적으로 재편하고 있습니다. 단순히 인산 수치를 조절하는 것에서 환자의 삶의 질을 개선하는 것으로 초점이 이동하고 있으며, 이는 시장 성장의 원동력이 될 뿐만 아니라 만성 신장 질환 환자의 장기적인 건강 결과를 개선하는 데에도 기여하고 있습니다.

고인산혈증 치료제 시장의 최근 동향

최근 고인산혈증 치료제 시장의 트렌드는 치료 효과 개선, 부작용 감소, 환자 편의성 향상에 초점이 맞추어져 있습니다. 이번 개발은 만성 신장 질환 환자의 인산 수치 상승 관리라는 고질적인 문제에 대한 직접적인 대응책입니다. 목표는 환자의 다양한 요구와 기호에 맞는 종합적인 치료법을 제공하여 장기적인 건강 결과를 개선하는 것입니다.

• NHE3 억제제 승인: 중요한 발전은 테나파놀과 같은 NHE3 억제제의 승인과 상업화입니다. 그 영향은 기존의 인산 결합제를 대체하는 새로운 작용기전의 약제 유형이 도입되었습니다는 것입니다. 이를 통해 기존 치료제에 내성이 있거나 충분한 효과를 얻지 못하는 환자들에게 새로운 치료 옵션을 제공할 수 있게 되었습니다.
• 철제 바인더의 발전: 주요 개발은 더 나은 안전성과 유효성 프로파일을 제공하는 차세대 철제 인산염 바인더의 출시입니다. 이는 철분 결핍에 대한 대응이라는 두 가지 이점을 겸비한 인산염 조절의 개선입니다. 옥시수산화수크로페릭과 같은 첨단 결합제는 부작용이 적고 치료적 부가가치가 높기 때문에 채택이 증가하고 있습니다.
• 전략적 제휴 및 인수: 시장에서는 제약사 간 전략적 제휴 및 인수합병이 활발히 진행되고 있습니다. 그 결과, 연구개발과 시장 확대가 가속화되고 있습니다. 이러한 제휴를 통해 양사는 서로의 전문 지식과 자원을 활용하여 고인산혈증 치료제의 개발 및 상용화를 보다 효율적으로 진행하고 시장을 통합하고 있습니다.
• 소아 적응증에 대한 집중: 최근 소아 환자에 특화된 고인산혈증 치료제 개발 및 승인 획득에 대한 관심이 집중되고 있습니다. 만성 신장 질환 소아 환자에게 더 빠르고 안전한 치료가 가능해집니다. 이를 통해 미충족 수요가 증가하여 소아 환자가 연령에 맞는 치료를 받을 수 있게 됩니다.
• 제네릭 의약품 출시: 인산염 결합제 제네릭 의약품 시장 개척이 이루어지고 있습니다. 그 결과, 치료비용이 절감되고 환자들의 접근성이 향상되고 있습니다. 세베라마 염산염과 같은 보다 저렴한 제네릭 의약품의 출시로 환자들의 순응도가 향상되고, 예산이 한정된 의료 시스템에서도 폭넓은 치료를 받을 수 있게 되었습니다.

이러한 개발은 치료의 전망을 넓히고 전반적인 효능을 향상시킴으로써 고인산혈증 치료제 시장에 큰 영향을 미치고 있습니다. 새로운 치료 메커니즘, 환자 편의성, 비용 효율성에 대한 관심은 시장 성장을 가속할 뿐만 아니라 만성 신장 질환 관리에 필수적인 약물로서의 역할을 확고히 하고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제5장 세계의 고인산혈증 치료제 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• 인산 알루미늄 결합제 : 동향과 예측(2019-2031년)
• 인산 철 결합제 : 동향과 예측(2019-2031년)
• 인산 마그네슘 결합제 : 동향과 예측(2019-2031년)
• 인산 칼슘 결합제 : 동향과 예측(2019-2031년)

제5장 세계의 고인산혈증 치료제 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• 병원 : 동향과 예측(2019-2031년)
• 진료소 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 세계의 고인산혈증 치료제 시장 : 지역별

제7장 북미의 고인산혈증 치료제 시장

• 개요
• 북미 고인산혈증 치료제 시장 : 유형별
• 북미 고인산혈증 치료제 시장 : 용도별
• 미국 고인산혈증 치료제 시장
• 멕시코 고인산혈증 치료제 시장
• 캐나다 고인산혈증 치료제 시장

제8장 유럽의 고인산혈증 치료제 시장

• 개요
• 유럽 고인산혈증 치료제 시장 : 유형별
• 유럽 고인산혈증 치료제 시장 : 용도별
• 독일 고인산혈증 치료제 시장
• 프랑스 고인산혈증 치료제 시장
• 스페인 고인산혈증 치료제 시장
• 이탈리아 고인산혈증 치료제 시장
• 영국 고인산혈증 치료제 시장

제9장 아시아태평양의 고인산혈증 치료제 시장

• 개요
• 아시아태평양 고인산혈증 치료제 시장 : 유형별
• 아시아태평양 고인산혈증 치료제 시장 : 용도별
• 일본 고인산혈증 치료제 시장
• 인도 고인산혈증 치료제 시장
• 중국 고인산혈증 치료제 시장
• 한국 고인산혈증 치료제 시장
• 인도네시아 고인산혈증 치료제 시장

제10장 기타 지역(ROW)의 고인산혈증 치료제 시장

• 개요
• 기타 지역 고인산혈증 치료제 시장 : 유형별
• 기타 지역 고인산혈증 치료제 시장 : 용도별
• 중동 고인산혈증 치료제 시장
• 남미 고인산혈증 치료제 시장
• 아프리카 고인산혈증 치료제 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 바이어의 교섭력
  • 공급업체의 교섭력
  • 대체품의 위협
  • 신규 진출업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 유형별
  • 성장 기회 : 용도별
• 세계 고인산혈증 치료제 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 인수합병(M&A), 계약, 제휴 및 합작투자(JV)

제13장 밸류체인 주요 기업 개요

• 경쟁 분석
• Keryx Biopharmaceuticals
• Sanofi
• Takeda
• Vifor Pharma
• Amgen

제14장 부록

• 그림 리스트
• 표 리스트
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel에 대해
• 문의

영문목차

The future of the global hyperphosphatemia drug market looks promising with opportunities in the hospital and clinic markets. The global hyperphosphatemia drug market is expected to grow with a CAGR of 4.9% from 2025 to 2031. The major drivers for this market are the increasing prevalence of chronic kidney diseases, the rising demand for effective phosphate control, and the growing focus on improving patient outcomes.

• Lucintel forecasts that, within the type category, calcium phosphate binder is expected to witness the highest growth over the forecast period.
• Within the application category, hospital is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Hyperphosphatemia Drug Market

Emerging trends are reshaping the hyperphosphatemia drug market by focusing on more effective, convenient, and targeted treatments. These trends are a direct response to the limitations of traditional therapies, such as high pill burden and side effects. They are moving the market towards a future where treatment is more personalized, offering better adherence and improved long-term patient outcomes.

• Shift to Non-Calcium-Based Binders: A key trend is the move away from calcium-based phosphate binders due to concerns about hypercalcemia and vascular calcification. The impact is a safer treatment profile. Newer non-calcium binders, such as those based on iron or lanthanum, offer effective phosphate control without the risk of these side effects, leading to better cardiovascular outcomes in CKD patients.
• Development of Novel Mechanisms: The market is seeing a trend toward drugs with new mechanisms of action, such as NHE3 inhibitors. The impact is a reduction in pill burden and an expansion of treatment options. Drugs like tenapanor, which inhibit intestinal phosphate absorption, offer a new way to manage hyperphosphatemia and can be used alone or in combination with traditional binders.
• Focus on Pill Burden reduction: A major trend is the development of therapies that reduce the number of pills a patient must take daily. The impact is improved patient adherence and a higher quality of life. The high pill burden of traditional phosphate binders is a significant barrier to compliance, so new formulations and drugs that require fewer doses are highly valued by patients and clinicians.
• Integration of Technology & Digital Health: The market is seeing a growing trend of integrating digital tools and mobile apps to improve treatment adherence. The impact is better patient engagement and management. These tools can help patients track their phosphate levels, monitor their diet, and remind them to take their medication, thereby complementing pharmacological treatments and improving overall outcomes.
• Expansion of Oral Formulations: A key trend is the development of more palatable and convenient oral formulations, such as chewable tablets and liquid suspensions. The impact is a significant improvement in patient comfort and compliance. These formulations are particularly beneficial for patients who have difficulty swallowing pills, making treatment more accessible and tolerable.

These emerging trends are fundamentally reshaping the hyperphosphatemia drug market by moving it towards a more patient-centric model of care. The focus has shifted from simply controlling phosphate levels to improving patient quality of life, which is not only driving market growth but also leading to better long-term health outcomes for individuals with chronic kidney disease.

Recent Developments in the Hyperphosphatemia Drug Market

Recent developments in the hyperphosphatemia drug market are focused on improving treatment efficacy, reducing side effects, and enhancing patient convenience. These developments are a direct response to the persistent challenges of managing elevated phosphate levels in patients with chronic kidney disease. The goal is to provide a comprehensive range of therapies that cater to different patient needs and preferences, leading to better long-term health outcomes.

• Approval of NHE3 Inhibitors: A significant development is the regulatory approval and commercialization of NHE3 inhibitors, such as tenapanor. The impact is the introduction of a new class of drugs with a novel mechanism of action, offering an alternative to traditional phosphate binders. This provides a new option for patients who are intolerant to or have an inadequate response to existing therapies.
• Advancements in Iron-Based Binders: A key development is the launch of next-generation iron-based phosphate binders that offer a better safety and efficacy profile. The impact is improved phosphate control with a dual benefit of addressing iron deficiency. These advanced binders, such as sucroferric oxyhydroxide, are increasingly being adopted due to their lower side effects and added therapeutic value.
• Strategic Partnerships & Acquisitions: The market has seen a development in strategic partnerships and acquisitions among pharmaceutical companies. The impact is an acceleration of R&D and market expansion. These collaborations allow companies to leverage each other's expertise and resources to develop and commercialize new hyperphosphatemia drugs more efficiently, consolidating the market.
• Focus on Pediatric Indications: Recent developments include a growing focus on developing and getting approval for hyperphosphatemia drugs specifically for pediatric patients. The impact is an earlier and safer intervention for children with chronic kidney disease. This addresses a significant unmet need and ensures that younger patients have access to tailored, age-appropriate treatments.
• Launch of Generic Formulations: The market is seeing a development in the launch of generic versions of established phosphate binders. The impact is a reduction in treatment costs and an increase in patient access. The availability of more affordable generics, such as sevelamer hydrochloride, helps to improve patient adherence and makes a wider range of treatments available to healthcare systems with limited budgets.

These developments are having a profound impact on the hyperphosphatemia drug market by expanding the treatment landscape and improving its overall effectiveness. The focus on new therapeutic mechanisms, patient convenience, and cost-effectiveness is not only driving market growth but also solidifying the role of these drugs as an essential part of chronic kidney disease management.

Strategic Growth Opportunities in the Hyperphosphatemia Drug Market

Strategic growth opportunities in the hyperphosphatemia drug market are concentrated on expanding the use of these therapies across a wider patient population and for different stages of chronic kidney disease. These opportunities are driven by the rising prevalence of the disease and the need for more effective, convenient, and long-lasting treatments. The focus is on leveraging innovation to address unmet clinical needs and improve quality of life.

• Non-Dialysis CKD Patients: A major growth opportunity lies in targeting hyperphosphatemia in non-dialysis chronic kidney disease (CKD) patients. The impact is an earlier intervention that can help prevent disease progression and delay the need for dialysis. As awareness of hyperphosphatemia's risks increases, this patient segment represents a significant area for market expansion.
• Pediatric Hyperphosphatemia: The pediatric hyperphosphatemia market represents a strategic growth opportunity, as there is a significant need for safe and effective treatments tailored for children. The impact is an earlier and more effective management of the condition in young patients, leading to better long-term developmental outcomes and a higher quality of life.
• Combination and Adjunctive Therapies: There is a growth opportunity in developing therapies that can be used in combination with existing phosphate binders. The impact is enhanced efficacy and a more personalized approach to care. For patients who do not respond fully to a single therapy, a combination approach could offer a more effective solution, addressing a significant unmet need and improving outcomes.
• Emerging Market Penetration: Penetrating emerging markets with cost-effective and accessible therapies is a long-term growth opportunity. The impact is a significant increase in the global patient population receiving treatment. With the rising prevalence of chronic kidney disease in regions like China and India, there is a large, underserved patient population that represents a key area for future market expansion.
• Home Dialysis and Home Care: A key growth opportunity is in developing therapies and formulations suitable for patients on home dialysis or in home-care settings. The impact is greater patient autonomy and convenience. As home-based care becomes more prevalent, there is a growing demand for treatments that are easy to administer and manage outside of a clinical setting, reducing the burden on both patients and the healthcare system.

These strategic growth opportunities are reshaping the hyperphosphatemia drug market by diversifying its applications and integrating it into a broader global healthcare landscape. The focus on new patient populations, convenient delivery methods, and preventive care is driving market innovation and positioning hyperphosphatemia drugs as a critical area of growth in chronic disease management.

Hyperphosphatemia Drug Market Driver and Challenges

Major drivers and challenges impacting the hyperphosphatemia drug market are a complex interplay of technological, economic, and regulatory factors. These forces are influencing market growth and shaping the competitive landscape. While the increasing prevalence of chronic kidney disease and advancements in non-calcium-based binders are propelling the market forward, issues related to high costs, patient non-adherence, and regulatory hurdles pose significant hurdles.

The factors responsible for driving the hyperphosphatemia drug market include:

1. Rising CKD and ESRD Prevalence: The increasing global prevalence of chronic kidney disease and end-stage renal disease is a primary market driver. This growing patient pool creates a pressing need for effective therapeutic solutions, fueling research and development efforts and ensuring a sustained demand for a wide range of treatments to manage the disease.

2. Technological Advancements: Significant technological advancements in drug development have led to the creation of more targeted and effective therapies. This is a major driver as new treatments, such as NHE3 inhibitors and non-calcium-based binders, offer superior efficacy and a better side-effect profile, leading to improved patient outcomes and higher market adoption.

3. Growing Awareness: A global increase in awareness of the risks and complications associated with hyperphosphatemia is a key driver. This heightened knowledge among both patients and physicians leads to earlier diagnosis and a greater emphasis on aggressive management, thereby increasing the number of patients seeking and receiving treatment.

4. Shift to Non-Calciumbased Binders: The growing preference for non-calcium-based phosphate binders over older calcium-based options is a major driver. This shift is driven by a focus on reducing the risk of vascular calcification and improving cardiovascular outcomes, which is a key concern in patients with chronic kidney disease.

5. Increasing Dialysis Population: The continuous growth in the global dialysis patient population is a significant driver. Hyperphosphatemia is a common complication in these patients, and the need for ongoing management ensures a steady demand for phosphate binders and other therapeutic options to control serum phosphorus levels.

Challenges in the hyperphosphatemia drug market are:

1. Patient Non-Adherence: A key challenge is the high rate of patient non-adherence to hyperphosphatemia treatment, primarily due to the high pill burden and gastrointestinal side effects. This limits the effectiveness of the drugs and can lead to poor clinical outcomes, which is a significant barrier for both patients and healthcare providers.

2. High Cost of Treatment: The significant cost of novel hyperphosphatemia drugs, particularly the advanced non-calcium-based options, is a major challenge. This financial barrier can limit patient access to these life-changing medications and create a significant affordability issue, particularly in regions with limited healthcare budgets.

3. Stringent Regulatory Hurdles: Stringent and evolving regulatory guidelines for drug approval pose a significant challenge. Navigating these complex regulatory frameworks can be time-consuming and expensive for manufacturers, which can slow down product innovation and market entry, particularly for new and unconventional therapeutic agents.

The overall impact of these drivers and challenges is a market that is expanding, but with significant constraints. While the demand for effective therapies and a robust pipeline are creating a strong impetus for growth, issues of cost, patient adherence, and regulation are creating a competitive and sometimes restrictive environment. The market's future will depend on its ability to produce more affordable, convenient, and well-tolerated products to overcome these hurdles.

List of Hyperphosphatemia Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hyperphosphatemia drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hyperphosphatemia drug companies profiled in this report include-

• Keryx Biopharmaceuticals
• Sanofi
• Takeda
• Vifor Pharma
• Amgen

Hyperphosphatemia Drug Market by Segment

The study includes a forecast for the global hyperphosphatemia drug market by type, application, and region.

Hyperphosphatemia Drug Market by Type [Value from 2019 to 2031]:

• Aluminum Phosphate Binder
• Iron Phosphate Binder
• Magnesium Phosphate Binder
• Calcium Phosphate Binder

Hyperphosphatemia Drug Market by Application [Value from 2019 to 2031]:

• Hospitals
• Clinics
• Others

Country Wise Outlook for the Hyperphosphatemia Drug Market

The hyperphosphatemia drug market is experiencing significant developments driven by the rising global prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD). These developments are focused on creating more effective, tolerable, and convenient drug therapies to manage elevated phosphate levels, a condition that can lead to severe cardiovascular and bone-related complications. The market is moving towards a patient-centric approach with a focus on non-calcium-based binders and novel mechanisms of action.

• United States: The U.S. market is a leader in hyperphosphatemia drug innovation. Recent developments include the FDA approval of new non-phosphate binder drugs like tenapanor, which offers a new mechanism of action and reduces pill burden. Favorable reimbursement policies under the ESRD Prospective Payment System also encourage the adoption of novel and clinically effective treatments.
• China: China's market is rapidly expanding due to its large CKD patient population. Recent developments include the approval and launch of new-generation iron-based binders and the introduction of novel drugs like tenapanor. The government's focus on improving healthcare infrastructure and addressing the economic burden of chronic diseases is a key driver for market growth.
• Germany: In Germany, the market is defined by a strong emphasis on high-quality care and patient outcomes. Recent developments include a greater adoption of advanced non-calcium-based phosphate binders to reduce the risk of vascular calcification. The market is also seeing a push for personalized treatment strategies that consider the patient's overall health and comorbidities.
• India: The Indian market is growing steadily, propelled by a rising prevalence of CKD and a burgeoning dialysis patient population. Recent developments include an increase in domestic drug manufacturing and the launch of generic versions of established phosphate binders. This is helping to improve the accessibility and affordability of hyperphosphatemia treatments for a wider population.
• Japan: Japan's market is technologically advanced, with a strong focus on effective mineral metabolism management. Recent developments include the approval of tenapanor, which has shown efficacy as a single-agent drug and in reducing the pill burden associated with other phosphate binders. The country's high number of dialysis patients drives a continuous demand for new treatment options.

Features of the Global Hyperphosphatemia Drug Market

• Market Size Estimates: Hyperphosphatemia drug market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Hyperphosphatemia drug market size by type, application, and region in terms of value ($B).
• Regional Analysis: Hyperphosphatemia drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the hyperphosphatemia drug market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hyperphosphatemia drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the hyperphosphatemia drug market by type (aluminum phosphate binder, iron phosphate binder, magnesium phosphate binder, and calcium phosphate binder), application (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Hyperphosphatemia Drug Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Aluminum Phosphate Binder: Trends and Forecast (2019-2031)
• 4.4 Iron Phosphate Binder: Trends and Forecast (2019-2031)
• 4.5 Magnesium Phosphate Binder: Trends and Forecast (2019-2031)
• 4.6 Calcium Phosphate Binder: Trends and Forecast (2019-2031)

5. Global Hyperphosphatemia Drug Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospitals: Trends and Forecast (2019-2031)
• 5.4 Clinics: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Hyperphosphatemia Drug Market by Region

7. North American Hyperphosphatemia Drug Market

• 7.1 Overview
• 7.2 North American Hyperphosphatemia Drug Market by Type
• 7.3 North American Hyperphosphatemia Drug Market by Application
• 7.4 United States Hyperphosphatemia Drug Market
• 7.5 Mexican Hyperphosphatemia Drug Market
• 7.6 Canadian Hyperphosphatemia Drug Market

8. European Hyperphosphatemia Drug Market

• 8.1 Overview
• 8.2 European Hyperphosphatemia Drug Market by Type
• 8.3 European Hyperphosphatemia Drug Market by Application
• 8.4 German Hyperphosphatemia Drug Market
• 8.5 French Hyperphosphatemia Drug Market
• 8.6 Spanish Hyperphosphatemia Drug Market
• 8.7 Italian Hyperphosphatemia Drug Market
• 8.8 United Kingdom Hyperphosphatemia Drug Market

9. APAC Hyperphosphatemia Drug Market

• 9.1 Overview
• 9.2 APAC Hyperphosphatemia Drug Market by Type
• 9.3 APAC Hyperphosphatemia Drug Market by Application
• 9.4 Japanese Hyperphosphatemia Drug Market
• 9.5 Indian Hyperphosphatemia Drug Market
• 9.6 Chinese Hyperphosphatemia Drug Market
• 9.7 South Korean Hyperphosphatemia Drug Market
• 9.8 Indonesian Hyperphosphatemia Drug Market

10. ROW Hyperphosphatemia Drug Market

• 10.1 Overview
• 10.2 ROW Hyperphosphatemia Drug Market by Type
• 10.3 ROW Hyperphosphatemia Drug Market by Application
• 10.4 Middle Eastern Hyperphosphatemia Drug Market
• 10.5 South American Hyperphosphatemia Drug Market
• 10.6 African Hyperphosphatemia Drug Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Hyperphosphatemia Drug Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Keryx Biopharmaceuticals
  • Company Overview
  • Hyperphosphatemia Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Sanofi
  • Company Overview
  • Hyperphosphatemia Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Takeda
  • Company Overview
  • Hyperphosphatemia Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Vifor Pharma
  • Company Overview
  • Hyperphosphatemia Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Amgen
  • Company Overview
  • Hyperphosphatemia Drug Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us